Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZD6126 in newly diagnosed metastatic renal cell carcinoma
NCT00065572Phase 2Suspended
- Sponsor
- AstraZeneca
- Start
- Aug 2003
- Primary completion
- Feb 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ZD6126 in renal cell carcinoma (RCC), sponsored by AstraZeneca. Started Aug 2003; status: suspended.
02
Drugs
ZD6126
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00065572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00065572.